Contact Us

Defective Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



   * Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.



Ditropan Side Effects May Be Linked To Insomnia Lawsuits

Ditropan | Lawsuits, Lawyers | Side Effects: Hallucinations, Insomnia, Nervousness, Confusion, Central Nervous System

On April 9, 2007, the FDA released documents stating the Johnson and Johnson's drug Ditropan for overactive bladders needs stronger warnings about the threat of hallucinations and other related problems in children and older patients. The Food and Drug Administration originally approved Ditropan (generic: Oybutynin) in June 1999.

To date, the label for Ditropan already lists insomnia, nervousness, confusion and other central nervous system risks, but staff reviewers said more explicit cautions are needed. The FDA's gatherings state that, the labeling for Ditropan should point out that the drug can cause such problems and that the risks have been reported in patients taking the drug. It should furthermore call on doctors to monitor for symptoms, they wrote in a memo dated March 2007.

An FDA team evaluated 202 reports of central nervous system side effects in Ditropan patients; 37 in those 17 and younger and 143 in adults; no age was reported in 22 cases. Of those 202 reports mentioned hallucinations in 27% of the pediatric cases and in 25% of those aged 60 and older. Hallucinations were reported in 11% of cases for adults aged 17 to 59.

Legal Help For Victims Affected By Ditropan

If you or a loved one has taken Ditropan and experienced hallucinations or related side effects, please fill out the form at the right for a free case evaluation by a qualified defective drugs attorney. Alternatively, call 1-800-YOURLAWYER (1-800-968-7529).


DitropanRSS Feed

FDA: Bolster warning on bladder drug

Apr 10, 2007 | AP
Johnson & Johnson's bladder drug Ditropan needs stronger cau tions about the risk of hallucination and similar problems in children and older patients, Food and Drug Administration staff said in documents released yesterday. The drug, also known as oxybuty nin, already lists insomnia, nervous ness, confusion and other central nervous system risks on its label, but staff reviewers said more expli cit cautions are needed. Specifically, labeling should point out that the drug can cause such...

More Ditropan News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo